Perspective for CAR T-Cell Therapy in Underrepresented Populations: A Hypothesis-Generating CD19 Genomic Analysis

Area of Science:

• Genomics and Precision Oncology
• Immunotherapy and Pharmacogenomics

Background:

• Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has revolutionized B-cell malignancy treatment.
• Therapeutic challenges include antigen escape and limited long-term remission durability.
• Germline CD19 polymorphisms are understudied, especially in underrepresented Middle Eastern populations.

Purpose of the Study:

• To characterize CD19 variants in Arab populations relevant to CAR T-cell immunotherapy.
• To address the knowledge gap in pharmacogenomic data for Middle Eastern individuals.
• To explore the potential impact of germline variation on immunotherapy outcomes.

Main Methods:

• Analysis of publicly available whole-exome sequencing data from 1196 individuals of Arab origin.
• Identification and frequency analysis of CD19 variants.
• Computational analysis to assess potential relevance to CAR T-cell therapy.

Main Results:

• The L174V (rs2904880) CD19 variant was identified with a V/V genotype frequency of 65.3%.
• A significant deviation from Hardy-Weinberg equilibrium was observed (p < 0.00001), potentially linked to consanguinity.
• No direct clinical or functional impact of the variant could be established computationally.

Conclusions:

• Distinctive genetic architectures in consanguineous populations may offer unique insights into germline variation's role in precision oncology.
• Further functional validation is required to determine the clinical relevance of CD19 germline variants in CAR T-cell therapy.
• Investigating these variations can help mitigate global health disparities in immunotherapy access.